Company Eurofins Scientific SE Deutsche Boerse AG
Equities
ESF
FR0000038259
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
53.62 EUR | -1.07% | -4.59% | -9.73% |
29/04 | CAC40: France's rating maintained = non-event | CF |
29/04 | CAC40: starts the week slightly up, crosses the 8100 mark | CF |
Business Summary
At the end of 2023, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 900 laboratories located throughout the world.
Net sales are distributed geographically as follows: Europe (50.7%), North America (38.5%) and other (10.8%).
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sample-based
82.7
%
| 5,588 | 83.3 % | 5,388 | 82.7 % | -3.59% |
Study-based
8.3
%
| 572 | 8.5 % | 541 | 8.3 % | -5.37% |
Full Time Equivalent-based
6.9
%
| 426 | 6.4 % | 449 | 6.9 % | +5.28% |
Product-based
2.1
%
| 126 | 1.9 % | 137 | 2.1 % | +8.73% |
Other
0.0
%
| 0 | 0.0 % | 0 | 0.0 % | +100.00% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
50.8
%
| 3,507 | 52.2 % | 3,306 | 50.8 % | -5.72% |
North America
38.5
%
| 2,494 | 37.2 % | 2,507 | 38.5 % | +0.52% |
Rest of the World
10.8
%
| 711 | 10.6 % | 701 | 10.8 % | -1.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 61 | 01/87/01 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/15/01 |
Christian Wurst
COO | Chief Operating Officer | - | 01/19/01 |
Yves-Loïc Martin
BRD | Director/Board Member | 58 | 01/92/01 |
François Vigneau
PRN | Corporate Officer/Principal | 58 | 01/96/01 |
Corporate Officer/Principal | 41 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 61 | 01/87/01 |
Yves-Loïc Martin
BRD | Director/Board Member | 58 | 01/92/01 |
Valérie Hanote
BRD | Director/Board Member | 58 | 01/91/01 |
Director/Board Member | 69 | 24/14/24 | |
Director/Board Member | 60 | 20/17/20 | |
Evie Roos
BRD | Director/Board Member | 56 | - |
Pascal Rakovsky
BRD | Director/Board Member | 65 | 01/20/01 |
Ivo Rauh
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 192,981,183 | 128,871,845 ( 66.78 %) | 955,858 ( 0.4953 %) | 66.78 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
EUROFINS CEREP 95.76% | 4,831 | 95.76% | 120,002,043 $ |
EUROFINS SCIENTIFIC SE 0.50% | 955,858 | 0.50% | 60,989,858 $ |
VIMTA LABS LIMITED 19.86% | 4,403,668 | 19.86% | 23,474,985 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Wiener Neudorf Palmersstraße Real Estate GmbH
| |
Eurofins GeneScan Holding GmbH
Eurofins GeneScan Holding GmbH Miscellaneous Commercial ServicesCommercial Services Part of Eurofins Scientific SE, Eurofins GeneScan Holding GmbH is a world leader in food, environment, pharma product testing & agroscience CRO services. The private company is based in Freiburg im Breisgau, Germany. With a network of more than 1,000 independent companies (900 laboratories) in 61 countries, Eurofins GeneScan Holding offers over 200,000 analytical methods. The CEO of the German company is Gilles G. Martin. |
Miscellaneous Commercial Services
|
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.69% | 70.69B | |
+14.32% | 81.84B | |
+9.37% | 29.03B | |
-11.43% | 16.97B | |
+0.43% | 16.83B | |
-0.24% | 15.28B | |
+6.59% | 12.41B | |
+33.40% | 12.26B | |
-31.05% | 11.83B |
- Stock Market
- Equities
- ERF Stock
- ESF Stock
- Company Eurofins Scientific SE